開示日時：2022/05/25 11:00:00
損益
| 決算期 | 売上高 | 営業益 | 経常益 | EPS |
| 2018.03 | 46,683,800 | 8,817,300 | 8,817,300 | 134.53 |
| 2019.03 | 45,926,700 | 5,788,400 | 5,788,400 | 122.39 |
| 2020.03 | 48,273,200 | 8,323,900 | 8,323,900 | 102.58 |
| 2021.03 | 51,595,200 | 7,122,400 | 7,122,400 | 141.5 |
※金額の単位は［万円］
株価
| 前日終値 | 50日平均 | 200日平均 | 実績PER | 予想PER |
| 1,407.0 | 1,409.62 | 1,874.71 | 9.83 | 11.12 |
※金額の単位は［円］
キャッシュフロー
| 決算期 | フリーCF | 営業CF |
| 2018.03 | 8,106,600 | 9,342,000 |
| 2019.03 | 3,579,700 | 4,871,100 |
| 2020.03 | 3,277,700 | 4,612,800 |
| 2021.03 | 12,479,500 | 13,560,100 |
※金額の単位は［万円］
▼テキスト箇所の抽出
May 25, 2022 Sumitomo Pharma Co., Ltd. Corrections to “Supplementary Financial Data (IFRS) for the Year Ended March 31, 2022” Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura; Securities Code: 4506, Prime Market of TSE) announced today that the Company has corrected misdescription in a part of the description of the capital expenditures/depreciation and amortization on page 2 and the major consolidated subsidiaries on page 8 of Supplementary Financial Data (IFRS) for the Year Ended March 31, 2022, as follows. The corrected items are indicated with underline. 【Page 2 Capital expenditures】 (Before corrections) (Billions of yen) FY2020 FY2021 Change Change FY2022 (Forecast) 12.7 12.7 (0.0) 15.9 3.2 (Billions of yen) FY2020 FY2021 Change Change FY2022 (Forecast) 12.7 12.6 (0.0) 15.9 3.3 5. Capital Expenditures/ Depreciation and Capital expenditures (After corrections) 5. Capital Expenditures/ Depreciation and Amortization Capital expenditures 【Page 8 Major Consolidated Subsidiaries】 (Before corrections) Domestic Sumitomo Pharma Food & Chemical Co., Ltd. Sumitomo Pharma Animal Health Co., Ltd. Sumitomo Pharma Promo Co., Ltd. Overseas Sumitomo Pharma America Holdings, Inc. Sunovion Pharmaceuticals Inc. Sumitomo Pharma Oncology, Inc. Sumitovant Biopharma, Inc. Myovant Sciences Ltd. Urovant Sciences Ltd. 1 Number of employees 204 94 38 Number of employees 164 *1,210 190 102 *565 *302 Enzyvant Therapeutics Ltd. Altavant Sciences Ltd. Spirovant Sciences Ltd. Sumitomo Pharma (Suzhou) Co., Ltd. (Reference) Number of employees consolidated / non-consolidated 7,023 3,074 March 31, 2022 (After corrections) *30 *20 *34 774 Domestic Sumitomo Pharma Food & Chemical Co., Ltd. Sumitomo Pharma Animal Health Co., Ltd. Sumitomo Pharma Promo Co., Ltd. Overseas Sumitomo Pharma America Holdings, Inc. Sunovion Pharmaceuticals Inc. Sumitomo Pharma Oncology, Inc. Sumitovant Biopharma, Inc. Myovant Sciences Ltd. Urovant Sciences Ltd. Enzyvant Therapeutics Ltd. Altavant Sciences Ltd. Spirovant Sciences, Inc. Sumitomo Pharma (Suzhou) Co., Ltd. Number of employees 202 96 34 Number of employees 168 *1,199 191 106 *569 *309 *32 *25 *37 758 (Reference) Number of employees March 31, 2022 consolidated / non-consolidated 6,987 3,040 Contact: Corporate Communications Sumitomo Pharma Co., Ltd. TEL: +81-6-6203-1407 (Osaka); +81-3-5159-3300 (Tokyo) 2
